Approximately 10 million Americans are cancer survivors living in their communities, and 80% of adult cancer care is delivered in the community oncology setting. To implement clinical trials, make progress at an appropriate pace in cancer medicine, and address the vital needs of an aging population, the clinical research infrastructure must extend into the community oncology setting. Our hypothesis is that enriched clinical trials in cancer control care, especially in the areas of symptom prevention, symptom management, integrative medicine, cancer prevention, cancer control, and cancer treatment can be delivered to patients via state-of-the art medicine in their communities through our Research"""""""" Base;and subsequently, important cancer care-related information and approaches can be transferred back from the community to M. D. Anderson Cancer Center to enhance our research programs and our understanding of cancer care. Our plan is to complete our existing cancer treatment trials, and to develop no further treatment trials. We will develop an expanded, focused program of cancer control research in response to the current needs of our community oncologists and the field of cancer medicine, the increased number of cancer survivors and the associated challenges in developing research-driven models of care for this population, and the evolving strengths of the M. D. Anderson research faculty.
The specific aims of this proposal are:
Aim 1. To conduct interventional clinical trials in the realm of cancer control to enhance the health of patients affected by cancer;Sub-aim 1a: To develop and conduct interventional clinical trials in the realm of palliative care and rehabilitation;Sub-aim 1b: To develop and conduct interventional clinical trials in the realm of supportive oncology;Sub-aim 1c: To develop and conduct interventional trials that utilize interventions in the realm of integrative medicine (sometimes called complementary and alternative medicine);Sub-aim 1d: To develop and conduct interventional trials directed at improving the health of cancer survivors;Sub-aim 1e: To draw upon best practices in symptom assessment and measurement, and to expand the knowledge base in these realms through the conduct of interventional clinical trials that include patient-reported outcome measures;Sub-aim 1f: To incorporate novel Bayesian approaches to the design and analysis of clinical trials that include use of patient- reported outcomes.
Aim 2. To exchange medical information, scientific technology, and. best practice standards among our academic cancer center faculty and fellows, other academic centers, and community oncology sites through collaborative development of practical, innovative cancer control trials. Our Research Base is committed to directing our research program toward conducting clinical trials to meet our CCOP members'interests, skills, and practice settings while fulfilling the mission of M. D. Anderson and the NCI to eliminate suffering attributable to cancer and its treatments.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA045809-21
Application #
7663210
Study Section
Special Emphasis Panel (ZCA1-SRRB-3 (J1))
Program Officer
Kelaghan, Joseph
Project Start
1996-09-30
Project End
2012-05-31
Budget Start
2009-06-01
Budget End
2010-05-31
Support Year
21
Fiscal Year
2009
Total Cost
$2,091,787
Indirect Cost
Name
University of Texas MD Anderson Cancer Center
Department
Internal Medicine/Medicine
Type
Other Domestic Higher Education
DUNS #
800772139
City
Houston
State
TX
Country
United States
Zip Code
77030
Levin, Victor A; Ictech, Sandra E; Hess, Kenneth R (2018) Clinical importance of eflornithine (?-difluoromethylornithine) for the treatment of malignant gliomas. CNS Oncol 7:CNS16
Narayan, Hari K; Wei, Wei; Feng, Ziding et al. (2017) Cardiac mechanics and dysfunction with anthracyclines in the community: results from the PREDICT study. Open Heart 4:e000524
Spencer, Christine N; Lopez, Gabriel; Cohen, Lorenzo et al. (2016) Nurse and patient characteristics predict communication about complementary and alternative medicine. Cancer 122:1552-9
Siefker-Radtke, Arlene O; Campbell, Matthew T; Munsell, Mark F et al. (2016) Front-line Treatment with Gemcitabine, Paclitaxel, and Doxorubicin for Patients With Unresectable or Metastatic Urothelial Cancer and Poor Renal Function: Final Results from a Phase II Study. Urology 89:83-9
Mitri, Zahi; Karakas, Cansu; Wei, Caimiao et al. (2015) A phase 1 study with dose expansion of the CDK inhibitor dinaciclib (SCH 727965) in combination with epirubicin in patients with metastatic triple negative breast cancer. Invest New Drugs 33:890-4
Minasian, Lori M; Tangen, Catherine M; Wickerham, D Lawrence (2015) Ongoing Use of Data and Specimens From National Cancer Institute-Sponsored Cancer Prevention Clinical Trials in the Community Clinical Oncology Program. Semin Oncol 42:748-63
Lewis, Mark A; Zhao, Fengmin; Jones, Desiree et al. (2015) Neuropathic Symptoms and Their Risk Factors in Medical Oncology Outpatients With Colorectal vs. Breast, Lung, or Prostate Cancer: Results From a Prospective Multicenter Study. J Pain Symptom Manage 49:1016-24
Oki, Yasuhiro; Ewer, Michael S; Lenihan, Daniel J et al. (2015) Pegylated liposomal doxorubicin replacing conventional doxorubicin in standard R-CHOP chemotherapy for elderly patients with diffuse large B-cell lymphoma: an open label, single arm, phase II trial. Clin Lymphoma Myeloma Leuk 15:152-8
Bilen, Mehmet Asim; Johnson, Marcella M; Mathew, Paul et al. (2015) Randomized phase 2 study of bone-targeted therapy containing strontium-89 in advanced castrate-sensitive prostate cancer. Cancer 121:69-76
Penas-Prado, Marta; Hess, Kenneth R; Fisch, Michael J et al. (2015) Randomized phase II adjuvant factorial study of dose-dense temozolomide alone and in combination with isotretinoin, celecoxib, and/or thalidomide for glioblastoma. Neuro Oncol 17:266-73

Showing the most recent 10 out of 43 publications